newsfilter
← Latest News
GlobeNewswire·

Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment